PROTHENA CORP PLC (PRTA) Stock Fundamental Analysis
USA - NASDAQ:PRTA - IE00B91XRN20 - Common Stock
9.93 USD
-0.25 (-2.46%)
9.93 USD
0 (0%)
Taking everything into account, PRTA scores 3 out of 10 in our fundamental rating. PRTA was compared to 533 industry peers in the Biotechnology industry. PRTA has a great financial health rating, but its profitability evaluates not so good. PRTA is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
PRTA had negative earnings in the past year.
In the past year PRTA has reported a negative cash flow from operations.
In the past 5 years PRTA reported 4 times negative net income.
In the past 5 years PRTA reported 4 times negative operating cash flow.
1.2 Ratios
With a Return On Assets value of -79.53%, PRTA is not doing good in the industry: 67.61% of the companies in the same industry are doing better.
The Return On Equity of PRTA (-95.07%) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -79.53% | ||
| ROE | -95.07% | ||
| ROIC | N/A |
ROA(3y)-19.63%
ROA(5y)-16.25%
ROE(3y)-23.37%
ROE(5y)-23.22%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PRTA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
PRTA does not have a ROIC to compare to the WACC, probably because it is not profitable.
PRTA has more shares outstanding than it did 1 year ago.
The number of shares outstanding for PRTA has been increased compared to 5 years ago.
There is no outstanding debt for PRTA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -0.76, we must say that PRTA is in the distress zone and has some risk of bankruptcy.
PRTA has a Altman-Z score (-0.76) which is comparable to the rest of the industry.
PRTA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.76 |
ROIC/WACCN/A
WACC7.59%
2.3 Liquidity
PRTA has a Current Ratio of 6.61. This indicates that PRTA is financially healthy and has no problem in meeting its short term obligations.
PRTA has a better Current ratio (6.61) than 68.55% of its industry peers.
PRTA has a Quick Ratio of 6.61. This indicates that PRTA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 6.61, PRTA is in the better half of the industry, outperforming 68.93% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.61 | ||
| Quick Ratio | 6.61 |
3. Growth
3.1 Past
The earnings per share for PRTA have decreased strongly by -85.89% in the last year.
Looking at the last year, PRTA shows a very negative growth in Revenue. The Revenue has decreased by -91.16% in the last year.
The Revenue has been growing by 178.96% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-85.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%38.18%
Revenue 1Y (TTM)-91.16%
Revenue growth 3Y-12.33%
Revenue growth 5Y178.96%
Sales Q2Q%148.97%
3.2 Future
PRTA is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 3.62% yearly.
The Revenue is expected to decrease by -11.01% on average over the next years. This is quite bad
EPS Next Y-105.08%
EPS Next 2Y42.95%
EPS Next 3Y20.14%
EPS Next 5Y3.62%
Revenue Next Year-85.33%
Revenue Next 2Y6.43%
Revenue Next 3Y-32.75%
Revenue Next 5Y-11.01%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for PRTA. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 99.01, which means the current valuation is very expensive for PRTA.
Based on the Price/Forward Earnings ratio, PRTA is valued cheaper than 87.57% of the companies in the same industry.
PRTA is valuated expensively when we compare the Price/Forward Earnings ratio to 34.59, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 99.01 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PRTA's earnings are expected to grow with 20.14% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y42.95%
EPS Next 3Y20.14%
5. Dividend
5.1 Amount
No dividends for PRTA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
9.93
-0.25 (-2.46%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners79.74%
Inst Owner Change1.39%
Ins Owners19.24%
Ins Owner Change45.87%
Market Cap534.53M
Revenue(TTM)11.79M
Net Income(TTM)-280.46M
Analysts75.38
Price Target16.83 (69.49%)
Short Float %8.87%
Short Ratio4.81
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-12.94%
Min EPS beat(2)-28.86%
Max EPS beat(2)2.98%
EPS beat(4)1
Avg EPS beat(4)-10.08%
Min EPS beat(4)-28.86%
Max EPS beat(4)2.98%
EPS beat(8)3
Avg EPS beat(8)21.35%
EPS beat(12)6
Avg EPS beat(12)43.16%
EPS beat(16)6
Avg EPS beat(16)21.31%
Revenue beat(2)0
Avg Revenue beat(2)-41.76%
Min Revenue beat(2)-64.33%
Max Revenue beat(2)-19.2%
Revenue beat(4)0
Avg Revenue beat(4)-52.91%
Min Revenue beat(4)-72.37%
Max Revenue beat(4)-19.2%
Revenue beat(8)1
Avg Revenue beat(8)86.12%
Revenue beat(12)3
Avg Revenue beat(12)64.36%
Revenue beat(16)3
Avg Revenue beat(16)25.69%
PT rev (1m)37.5%
PT rev (3m)-28.7%
EPS NQ rev (1m)0.03%
EPS NQ rev (3m)26.9%
EPS NY rev (1m)0%
EPS NY rev (3m)-17.24%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.75%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-35.37%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 99.01 | ||
| P/S | 45.35 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.81 | ||
| P/tB | 1.81 | ||
| EV/EBITDA | N/A |
EPS(TTM)-4.61
EYN/A
EPS(NY)0.1
Fwd EY1.01%
FCF(TTM)-3.5
FCFYN/A
OCF(TTM)-3.49
OCFYN/A
SpS0.22
BVpS5.48
TBVpS5.48
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -79.53% | ||
| ROE | -95.07% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-19.63%
ROA(5y)-16.25%
ROE(3y)-23.37%
ROE(5y)-23.22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.03
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 20.16% | ||
| Cap/Sales | 1.54% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 6.61 | ||
| Quick Ratio | 6.61 | ||
| Altman-Z | -0.76 |
F-Score3
WACC7.59%
ROIC/WACCN/A
Cap/Depr(3y)132.78%
Cap/Depr(5y)92.67%
Cap/Sales(3y)1.38%
Cap/Sales(5y)5.33%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-85.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%38.18%
EPS Next Y-105.08%
EPS Next 2Y42.95%
EPS Next 3Y20.14%
EPS Next 5Y3.62%
Revenue 1Y (TTM)-91.16%
Revenue growth 3Y-12.33%
Revenue growth 5Y178.96%
Sales Q2Q%148.97%
Revenue Next Year-85.33%
Revenue Next 2Y6.43%
Revenue Next 3Y-32.75%
Revenue Next 5Y-11.01%
EBIT growth 1Y-32.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year100%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-110.54%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-113.92%
OCF growth 3YN/A
OCF growth 5YN/A
PROTHENA CORP PLC / PRTA FAQ
What is the ChartMill fundamental rating of PROTHENA CORP PLC (PRTA) stock?
ChartMill assigns a fundamental rating of 3 / 10 to PRTA.
Can you provide the valuation status for PROTHENA CORP PLC?
ChartMill assigns a valuation rating of 1 / 10 to PROTHENA CORP PLC (PRTA). This can be considered as Overvalued.
What is the profitability of PRTA stock?
PROTHENA CORP PLC (PRTA) has a profitability rating of 0 / 10.
What is the financial health of PROTHENA CORP PLC (PRTA) stock?
The financial health rating of PROTHENA CORP PLC (PRTA) is 7 / 10.